Yong-Jun Wang

Yong-Jun Wang

Auto-generated profile, based on publicly available information

Yong-Jun Wang

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
CWChao Wu
Chao Wu
YWYong-Jun Wang
Yong-Jun Wang
TLTie-Jun Liu
Tie-Jun Liu
HJHongzhong Jin
Hongzhong Jin
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disorder. Laboratory parameters may serve as an assessment tool, providing a potential objective window into disease activity. To systematically evaluate the utility of commonly obtained laboratory parameters in the objective assessment of disease severity in patients with HS. This single-center retrospective study included patients who were clinically diagnosed with HS, acne inversa, or follicular occlusion triad at Peking Union Medical College Hospital between January 1, 2020, and July 1, 2025. Study data were extracted from clinical examination records and corresponding laboratory test results. Ordinal logistic regression models were constructed to evaluate the associations between laboratory parameters and Hurley stages. Heterogeneity analyses were performed to assess the consistency of these associations across anatomical regions. The study included 1750 clinical visits from 583 HS patients, with a male predominance (85.7%) and a mean age of 31.15±12.11 years. By systematically comparing laboratory parameters across Hurley stages, this study identified significant differences in ten markers, including white blood cell (WBC), neutrophil ratio (NEU%), platelet (PLT), plateletcrit (PCT), mean platelet volume (MPV), hemoglobin (Hb), gamma-glutamyl transferase (GGT), high-density lipoprotein cholesterol (HDL-C), erythrocyte sedimentation rate (ESR), and high-sensitivity C-reactive protein (hsCRP). Ordinal logistic regression analyses demonstrated that WBC, NEU%, PLT, PCT, platelet distribution width (PDW), GGT, ESR, and hsCRP were significantly and positively associated with increasing Hurley stage, while Hb, MPV, and HDL-C exhibited inverse associations. Heterogeneity analysis found that systemic inflammation-related markers (WBC, PDW, ESR, and hsCRP) demonstrated highly consistent associations with HS severity across anatomical locations, while metabolic parameters (HDL-C, triglycerides (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)) exhibited significant site-specific heterogeneity. This study supports the use of readily available laboratory markers as an objective adjunct to conventional clinical severity assessments, while highlighting the anatomical specificity of HS pathophysiology.

1 September 2026 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
CWChao Wu
Chao Wu
XMXiao Ma
Xiao Ma
YWYong-Jun Wang
Yong-Jun Wang
TLTie-Jun Liu
Tie-Jun Liu
XZXin-Yuan Zhang
Xin-Yuan Zhang
HJHong-Zhong Jin
Hong-Zhong Jin
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease in which interleukin-17A (IL-17A) is an important therapeutic target. However, prospective real-world data on secukinumab (IL-17A inhibitor) safety and efficacy in Chinese patients with HS remain limited. Objective: To evaluate the 16-week efficacy and safety of secukinumab in Chinese patients with moderate-to-severe HS and explore potential treatment response predictors. Methods: This single-center, prospective, real-world cohort study included 31 patients with moderate-to-severe HS. The patients received subcutaneous secukinumab 300 mg weekly for 5 weeks, followed by administration either every 2 (1 patient [3.23%]) or 4 (30 patients [96.77%]) weeks. Concomitant therapies were allowed when clinically indicated. The primary endpoint was Hidradenitis Suppurativa Clinical Response (HiSCR) at week 16. Secondary endpoints included changes in inflammatory nodule, abscess, and draining tunnel counts, International Hidradenitis Suppurativa Severity Score System (IHS4), Numeric Rating Scale (NRS) for pain, Dermatology Life Quality Index (DLQI), adverse events, and exploratory predictors of HiSCR. Results: The cohort was predominantly male (77.42%). Ten patients (32.26%) were classified as Hurley stage II and 21 (67.74%) as Hurley stage III. During treatment, 74.19% of patients received concomitant therapies. At week 16, HiSCR was achieved by 17/31 patients (54.84%). Inflammatory nodule counts, draining tunnel counts, IHS4, and DLQI significantly decreased. In the adjusted multivariate logistic regression model, after adjustment for prior biologic use, decreased high-density lipoprotein cholesterol, and dyslipidemia, elevated triglyceride was independently associated with HiSCR achievement (β= 3.246, p = 0.037). Adverse events were mild, including acne in two patients (6.45%), facial allergic dermatitis in one (3.23%), fever in two (6.45%), and fatigue in one (3.23%). None discontinued treatment because of adverse events. Conclusions: Secukinumab demonstrated meaningful 16-week efficacy and favorable safety in Chinese patients with moderate-to-severe HS. Elevated triglyceride was associated with treatment response in this exploratory analysis; however, further validation in larger cohorts is required.